Mayinglong Pharmaceutical Group's announcement on the implementation of annual equity distribution in 2023.
Announcement from Mayinglong Pharmaceutical Group regarding its wholly-owned subsidiary obtaining a pharmaceutical registration certificate.
Mayinglong Pharmaceutical Group's Annual Shareholders' Meeting Legal Opinion Letter for 2023.
Mayinglong Pharmaceutical Group's announcement of the resolution of the 2023 Annual Shareholders Meeting.
Announcement of Mayinglong Pharmaceutical Group about holding the 2023 annual and 2024 first quarter performance briefing.
Mayinglong Pharmaceutical Group's 2023 Annual Shareholders Meeting materials.
Announcement on Shareholder Renaming by Mayinglong Pharmaceutical Group
Ma Yinglong Announces Resolutions of the 14th Meeting of the 11th Board of Directors
Ma Yinglong's announcement on the renewal of the 2024 accounting firm
Ma Yinglong's announcement on convening the 2023 Annual General Meeting of Shareholders
Ma Yinglong's Notice on Participating in the 2024 Online Investor Group Reception Day for Listed Companies in Hubei
Ma Yinglong's 2024 First Quarter Report
Ma Yinglong's announcement on obtaining a drug registration certificate
Ma Yinglong\'s 2023 Audit Report
Ma Yinglong\'s 2023 Annual Report Summary
Ma Yinglong\'s special review report on the 2023 summary table of non-operating capital occupation and other related capital transactions
Ma Yinglong's 2023 Independent Director Debriefing Report (Zhang Yonghui)
Ma Yinglong's 2023 Annual Report
Ma Yinglong\'s 2023 Internal Control Evaluation Report
Ma Yinglong's 2023 Environmental, Social and Governance (ESG) Report
No Data